Librexia Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Librexia Program. Real-time updates on events, politics, business and more.

Johnson & Johnson : 2023 Second-Quarter Press Release & Supplemental Schedules

July 20, 2023

FOR IMMEDIATE RELEASE 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational...

United States Joaquin Duato Biosense Webster Exchange Commission Receptor Antagonist Peptide In Development Johnson Announces Launch Of Kenvue Inc

Source: marketscreener.com

Johnson & Johnson Reports Q2 2023 Results

July 20, 2023

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of...

United States Joaquin Duato Biosense Webster Kenvue Inc Women Health Company Consumer Health

Source: marketscreener.com

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

May 25, 2023

The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients,... | May 25, 2023

Bristol Myers Squibb Bristol Myers Squibb Janssen Arthurl Bloomfield Johnson Janssen Robert Harrington Xia Fxia

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Librexia Program News Today

Johnson & Johnson : 2023 Second-Quarter Press Release & Supplemental Schedules

Johnson & Johnson Reports Q2 2023 Results

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

Explore More Categories